Kohjin Bio Co., Ltd. (TYO:177A)

Japan · Delayed Price · Currency is JPY

845.00

-2.00 (-0.24%)

Aug 27, 2026, 3:30 PM JST

-50.93% (1Y)

Market Cap	4.33B -51.5%
Revenue (ttm)	4.69B -9.5%
Net Income	128.00M -82.1%
EPS	25.04 -82.1%
Shares Out	5.11M
PE Ratio	33.82
Forward PE	n/a
Dividend	10.00 (1.17%)
Ex-Dividend Date	Mar 30, 2026

Volume	2,800
Open	840.00
Previous Close	847.00
Day's Range	840.00 - 852.00
52-Week Range	836.00 - 2,020.00
Beta	0.00
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Kohjin Bio

Kohjin Bio Co., Ltd. manufactures and sells animal blood, serum, tissue culture media, media for microbiology testing, in vitro diagnostic agents, and cosmetics. It operates through Tissue Culture Business, Microbiology Business, and Cell Processing Business segments. The company offers tissue culture mediums for human cell culture, including human lymphocyte culture, hepatoblastoma-derived cell lines, adipose- derived stem cells, neural stem cells, fibroblast, vascular endothelial cells, and epidermal keratinocyte human cell cultures, as well ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1981

Employees 176

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 177A

Full Company Profile

Financial Performance

In fiscal year 2026, Kohjin Bio's revenue was 4.94 billion, a decrease of -5.13% compared to the previous year's 5.21 billion. Earnings were 251.00 million, a decrease of -68.39%.

Financial Statements